TY - JOUR
T1 - Guidelines for Pediatric Unrelated Cord Blood Transplantation—Unique Considerations
AU - American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group
AU - Dahlberg, Ann
AU - Kurtzberg, Joanne
AU - Boelens, Jaap
AU - Martinez, Caridad
AU - Carpenter, Paul
AU - Tewari, Priti
N1 - Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy
PY - 2021/12
Y1 - 2021/12
N2 - Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT.
AB - Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT.
KW - Guidelines
KW - Pediatric cord blood transplantation
UR - http://www.scopus.com/inward/record.url?scp=85120732977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120732977&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.09.013
DO - 10.1016/j.jtct.2021.09.013
M3 - Article
C2 - 34571212
AN - SCOPUS:85120732977
SN - 2666-6367
VL - 27
SP - 968
EP - 972
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 12
ER -